Humacyte’s (HUMA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA) in a report released on Friday, Marketbeat reports. The firm currently has a $15.00 price target on the stock, up from their prior price target of $12.00.

Several other research analysts have also issued reports on HUMA. D. Boral Capital reiterated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research report on Thursday, November 21st. BTIG Research reiterated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. Benchmark reissued a “buy” rating and set a $15.00 price objective on shares of Humacyte in a report on Thursday, October 10th. Piper Sandler set a $6.00 target price on Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. Finally, TD Cowen reissued a “buy” rating and set a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Humacyte has an average rating of “Buy” and a consensus target price of $13.43.

Humacyte Trading Up 34.1 %

Shares of Humacyte stock opened at $4.64 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. Humacyte has a 1 year low of $2.48 and a 1 year high of $9.97. The firm has a market cap of $583.99 million, a PE ratio of -3.46 and a beta of 1.38. The company has a 50 day simple moving average of $4.83 and a two-hundred day simple moving average of $5.83.

Insiders Place Their Bets

In other Humacyte news, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Laura E. Niklason sold 811,172 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the transaction, the chief executive officer now directly owns 2,419,712 shares of the company’s stock, valued at approximately $10,743,521.28. This trade represents a 25.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,500,000 shares of company stock valued at $6,606,799 in the last ninety days. Company insiders own 11.20% of the company’s stock.

Institutional Trading of Humacyte

Several large investors have recently modified their holdings of HUMA. Renaissance Technologies LLC lifted its holdings in Humacyte by 693.0% in the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after buying an additional 524,600 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Humacyte during the third quarter valued at approximately $596,000. Thrivent Financial for Lutherans purchased a new stake in Humacyte in the third quarter worth $712,000. Millennium Management LLC lifted its stake in Humacyte by 504.3% in the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after acquiring an additional 1,334,641 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in Humacyte by 62.7% in the second quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company’s stock valued at $1,219,000 after acquiring an additional 97,931 shares in the last quarter. 44.71% of the stock is owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.